A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological Group

Eur Urol. 1994:26 Suppl 1:1-2. doi: 10.1159/000475421.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Delayed-Action Preparations
  • Drug Administration Schedule
  • Goserelin / administration & dosage*
  • Goserelin / therapeutic use
  • Humans
  • Injections, Subcutaneous
  • Male
  • Prostatic Neoplasms / drug therapy*

Substances

  • Delayed-Action Preparations
  • Goserelin